Business Context and Reporting Period
This Form 8-K Current Report is filed by Moleculin Biotech, Inc. (MBRX) for the reporting period ending September 15, 2026. The filing addresses a regulatory notice regarding the company's continued listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance: the closing bid price of the Common Stock remained below $1.00 per share for 30 consecutive business days from July 31, 2026, through September 11, 2026.
Material Changes
- Delisting Notice: The company received a Staff Determination Letter from Nasdaq on September 15, 2026, stating non-compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)).
- Compliance Period Ineligibility: The company is not eligible for the standard 180-day compliance period because it executed a 1-for-25 reverse stock split on December 1, 2025, within the prior one-year period.
Outlook, Risks, and Management Commentary
Management intends to request a hearing before the Nasdaq Hearings Panel to contest the delisting determination. A timely request will stay any suspension or delisting action pending the Panel's decision, allowing the stock to continue trading during the process. The filing explicitly states there is no assurance that the request for continued listing will be granted or that the company will regain compliance with the Minimum Bid Price Requirement.
Investor Verification Checklist
- Verify the status of the hearing request with the Nasdaq Hearings Panel.
- Monitor the daily closing bid price to assess if it remains below the $1.00 threshold.
- Review the company's recent 10-K and 10-Q filings for broader financial health context not included in this 8-K.
- Confirm whether the company has any pending capital raise plans to address the stock price deficiency.